Literature DB >> 9067054

Postoperative reparalysis after rocuronium following nebulized epinephrine.

G A Arndt1, T Gerry, P White.   

Abstract

PURPOSE: We report a case of postoperative reparalysis in the recovery room, following nebulized epinephrine. The patient was pharmacologically reversed with edrophonium after paralysis with rocuronium. CLINICAL
FINDINGS: A 12-yr-old girl developed postoperative reparalysis following the intraoperative administration of rocuronium. A total of 0.92 mg.kg-1 rocuronium was administered. After surgery, pharmacological reversal was achieved with 20 mg edrophonium with 0.15 mg atropine sulfate iv 35 min after the last administration of rocuronium. Muscular relaxation was monitored using an ulnar peripheral nerve stimulator (PNS). After reversal, a full train-of-four and sustained tetanus at 50 Hz were present. In the recovery room, following nebulized epinephrine, the patient became apneic. The patient was paralyzed and an ulnar PNS demonstrated only one faint twitch. The paralysis was reversed with 1.5 mg neostigmine with 0.3 mg glycopyrrolate.
CONCLUSION: Postoperative reparalysis following rocuronium may be a cause of postoperative respiratory distress. The definitive diagnosis is made using PNS and observing the response to pharmacological reversal. Nebulized epinephrine may have a previously undescribed role in the development of postoperative reparalysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067054     DOI: 10.1007/BF03015373

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  2 in total

1.  Sugammadex rescue following prolonged rocuronium neuromuscular blockade with 'recurarisation' in a patient with severe renal failure.

Authors:  Steven Lobaz; Mario Sammut; Anand Damodaran
Journal:  BMJ Case Rep       Date:  2013-02-07

2.  Small doses of epinephrine prolong the recovery from a rocuronium-induced neuromuscular block: a case report.

Authors:  Hubert J Schmitt
Journal:  BMC Anesthesiol       Date:  2018-07-11       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.